Acute aortic dissection caused by fruquintinib for metastatic colorectal cancer-a case report and literature review.

ABSTRACT:

Background

Fruquintinib is a highly selective tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR). At present, it has been approved for third-line therapy for advanced metastatic colorectal cancer in China. Like other small-molecule tyrosine kinase inhibitors, adverse reactions such as hand-foot syndrome, hypertension and cardiotoxicity may be seen. However, acute aortic dissection caused by fruquintinib has not been reported so far.

Case description

Here, we report a case of aortic dissection. The patient, a 61-year-old man with advanced metastatic colorectal cancer, without history of hypertension or other risk factors for aortic dissection, received fruquintinib as the third line of treatment. Six weeks after oral fruquintinib treatment

SUBMITTER: Deng YY 

PROVIDER: S-EPMC9906055 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature